Joshua Farb
Founder & Principal Consulting, CMC Process Development Elevate Bio
Speaker Bio: Josh Farb is the founder of Farb Consulting LLC, where he advises biotech leadership on RNA CMC strategy, GMP manufacturing, and IND-to-clinic execution. A global CMC executive with over 16 years of experience, Josh has built and scaled circRNA, mRNA, and biologics platforms from the ground up — delivering IND-enabling packages, GMP readiness, and clinical supply for novel therapeutics.
A recognized innovator, Josh holds patents in circRNA purification and enrichment, pioneered multi-column chromatography platforms, and integrated AI/uHTP analytics to optimize RNA sequence, structure, and performance. His leadership spans building high-performance teams, governing CDMO partnerships, and aligning R&D, Quality, Regulatory, and Commercial functions to accelerate timelines and de-risk supply chains.
Josh completed a postdoctoral fellowship in Cancer Biology & Molecular Oncology at Northwestern University Feinberg School of Medicine, holds a PhD in Biochemistry from the University of Vermont College of Medicine, and a BS in Biology/Chemistry from Springfield College. He is a frequent invited speaker at RNA therapeutics and bioprocessing conferences and has received multiple corporate awards for innovation, leadership, and safety excellence.
Seminars
- What are the most persistent challenges you face in reducing dsRNA impurities, and where are current purification approaches falling short?
- How are you balancing regulatory expectations for low impurity levels with the technical limitations of existing purification technologies?
- Which purification strategies, platforms, or resins have shown the most promise, and where do gaps still remain?
Key questions include:
- Are current circRNA purification strategies fundamentally overcomplicated – and where can we simplify without compromising quality?
- How do you balance purity, yield, and scalability when designing purification processes for clinical and commercial manufacturing?
- What will define a “fit-for-purpose” purification platform for circRNA as the field moves toward first-in-human and beyond?
- Overcoming Structural and Purification Bottlenecks: Explores how addressing the structural complexity of circular RNA (circRNA) allows for tunable purification strategies that simultaneously maximize yield, selectively remove small linear impurities, and consistently achieve ∼95% purity at milligram scales and greater for in vivo applications
- Correlating Purity and Sequence with Expression Dynamics: Highlights critical insights into how circRNA expression levels are tied directly to RNA purity, how translation duration is inversely correlated with immunostimulation, and how expression efficiency remains highly construct-specific based on primary sequence elements
- Advancing Analytics for Next-Gen Therapeutics: Demonstrates the application of stateof-the-art analytical approaches to rigorously confirm circularization and structural integrity, ultimately supporting the scalable, robust production of stable, next-generation RNA therapeutics
